Singh Vinay K, Jia Zongchao
CIHR Post-doctoral Fellow in Transdisciplinary Cancer Research, Queen's University, Department of Biochemistry, Kingston, Ontario, K7L 3N6, Canada.
Expert Opin Ther Targets. 2008 Jan;12(1):59-68. doi: 10.1517/14728222.12.1.59.
Expression of synuclein-gamma (SNCG) protein is elevated in the advanced stages of many types of cancers, including ovarian, lung, liver, esophagus, colon, prostate and, in particular, breast. In breast carcinoma, SNCG is causatively linked to stimulated proliferation, metastasis and drug resistance.
To establish SNCG as a potential therapeutic target and to discuss clinical use of SNCG inhibiting peptide.
This review focuses on the plausible mechanisms of SNCG activity, SNCG mediated drug resistance and its inhibition.
RESULTS/CONCLUSION: Evidence based research shows that the aberrant expression of SNCG has a strong correlation with breast cancer progression and poor clinical outcome. A peptide based inhibitor counters activity of SNCG, which may be developed as an adjuvant therapy.
在多种癌症的晚期阶段，包括卵巢癌、肺癌、肝癌、食管癌、结肠癌、前列腺癌，尤其是乳腺癌中，γ-突触核蛋白（SNCG）的表达会升高。在乳腺癌中，SNCG与增殖、转移及耐药性的增强存在因果关系。
将SNCG确立为潜在治疗靶点，并探讨SNCG抑制肽的临床应用。
本综述聚焦于SNCG活性、SNCG介导的耐药性及其抑制作用的可能机制。
结果/结论：基于证据的研究表明，SNCG的异常表达与乳腺癌进展及不良临床结局密切相关。一种基于肽的抑制剂可对抗SNCG的活性，有望开发为辅助治疗药物。
